Treace Medical Concepts Inc expected to post a loss of 27 cents a share - Earnings Preview

Treace Medical Concepts

02/11/2024 04:10

* Treace Medical Concepts Inc  TMCI.OQ   TMCI.O  is expected
to show a rise in quarterly revenue when it reports  results on
November 5 for the period ending January 1 0001
    * The Ponte Vedra Florida-based  company is expected to
report a
6.7% increase in revenue to $43.484 million from $40.76 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Treace Medical Concepts
Inc is
for a loss of 27 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 6
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Treace
Medical
Concepts Inc is $7.00​, above​ its last closing price of $4.78.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.29       -0.29      -0.29     Met     0
 Jan. 1 2024   -0.30       -0.30      -0.30     Met     0.9
 Dec. 31 2023  -0.09       -0.09      -0.10     Missed  -12.9​
 Sep. 30 2023  -0.25       -0.26      -0.28     Missed  -7.1
 ​​Jun.        -0.23       -0.24      -0.20     Beat    16.1
 30 2023                                                
 Mar. 31 2023  -0.23       -0.23      -0.23     Met     -0.7​
 Dec. 31 2022  -0.15       -0.14      -0.08     Beat    42.9
 Sep. 30 2022  -0.29       -0.29      -0.22     Beat    23.5
 This summary was machine generated November 2 at 04:10 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)